Acute myeloid leukemia (AML) in elderly patients is associated with poor prognosis. However, recent innovative maintenance therapies have reported improved outcomes in AML patients. This article summarizes the results of a multicenter, phase III, randomized trial that evaluated the benefits of adding androgens to maintenance therapy in elderly patients. More than 70% of patients with acute myeloid leukemia (AML) are older than 60 years of age at the time of diagnosis.
The prognosis of these patients is particularly poor due to the presence of comorbidities and a lower tolerance to intensive chemotherapies. In addition to higher treatment-related mortality, the complete remission rate achieved after induction chemotherapy is lower than that in young adults, and the remission duration is no longer than a year. Moreover, the overall survival of these patients rarely exceeds 15% beyond 5…
